Compare WAVE & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAVE | PRPO |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 38.3M |
| IPO Year | 2021 | 2000 |
| Metric | WAVE | PRPO |
|---|---|---|
| Price | $3.54 | $18.70 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.75 | N/A |
| AVG Volume (30 Days) | 9.8K | ★ 23.6K |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | N/A | $233.72 |
| Revenue Next Year | N/A | $22.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $3.65 | $17.79 |
| 52 Week High | $10.87 | $33.63 |
| Indicator | WAVE | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 30.23 | 41.09 |
| Support Level | N/A | $18.51 |
| Resistance Level | $4.92 | $24.89 |
| Average True Range (ATR) | 0.38 | 1.85 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 7.30 | 14.70 |
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient wave energy conversion, or WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographically, it has a presence in Israel, the USA, and Mexico.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.